NCT03406962: A trial that was reported late by Magenta Therapeutics, Inc.
This trial has reported, although it was 231 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03406962 |
|---|---|
| Title | A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 9, 2018 |
| Completion date | Feb. 10, 2020 |
| Required reporting date | Feb. 9, 2021, midnight |
| Actual reporting date | Sept. 29, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 231 |